8-K 1 v456442_8k.htm FORM 8-K















Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934



Date of report (Date of earliest event reported): December 30, 2016



Checkpoint Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)




(State or Other Jurisdiction

of Incorporation)


(Commission File Number)



(IRS Employer Identification No.)



2 Gansevoort Street, 9th Floor

New York, New York 10014

(Address of Principal Executive Offices)



(781) 652-4500

(Registrant's telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


  £ Written communications pursuant to Rule 425 under the Securities Act.
  £ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
  £ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
  £ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.







Item 1.01 Entry into a Material Definitive Agreement.


As of December 30, 2016, the Board of Directors (the “Board”) of Checkpoint Therapeutics, Inc. (the “Company”) by unanimous written consent, approved and authorized the execution of an advisory agreement dated January 1, 2017 (the “Advisory Agreement”) with Caribe BioAdvisors, LLC (the “Advisor”), owned by Michael S. Weiss (“Mr. Weiss”), the Chairman of the Board, to provide the board advisory services of Mr. Weiss as Chairman of the Board. Pursuant to the Advisory Agreement, the Advisor will be paid an annual cash fee of $60,000, in addition to any and all annual equity incentive grants paid to members of the Board.


As of December 30, 2016, the Company also entered into an extension of option agreement (the “Extension Agreement”) related to the option agreement dated March 17, 2015 (the “Option Agreement”) between TG Therapeutics, Inc. (“TG”) and the Company. The Extension Agreement further extends the option period of the Option Agreement to December 31, 2017.


This summary does not purport to be complete and is subject to and qualified in its entirety by reference to the text of the Advisory Agreement with the Advisor and the Extension Agreement with TG. 


 - 2 - 





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 


  Checkpoint Therapeutics, Inc.
Date:  January 6, 2017      
  By: /s/ James F. Oliviero
    James F. Oliviero
    President and Chief Executive Officer



 - 3 -